Evaluating the microbiome's role in predicting acute pancreatitis severity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the orointestinal microbiome and microbial-derived metabolome in patients diagnosed with acute pancreatitis to determine their potential as biomarkers for disease severity. Within 48 hours of hospital admission, buccal and rectal swabs, as well as stool and plasma samples, will be collected from participants. The study seeks to validate previous findings that suggest the microbiome can predict the course of acute pancreatitis more effectively than established clinical scores. By analyzing the microbiome's impact on disease severity, the research hopes to provide insights into the underlying mechanisms of acute pancreatitis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with initial diagnosis (\< 48h) of acute pancreatitis
* Age ≥ 18 years
* Patients able to understand/ give their written consent

Exclusion Criteria:

* Recurrent acute pancreatitis (\>2 previous episodes)
* Clinical or imaging signs of chronic pancreatitis
* Referred patients with length of hospital stay \> 48h

Where it's running

• University Medical Center Goettingen
  Göttingen, Lower Saxony, Germany Recruiting

Study contacts

• Study coordinator: Christoph Ammer-Herrmenau, Dr
• Email: christoph.herrmenau@med.uni-goettingen.de
• Phone: +491704075339

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Local complications of acute pancreatitis and postoperative pancreatic fistula: what happens in real life

  This multicenter registry tests how local pancreatic complications are managed in routine care and what outcomes look like over 180 days for adults.

  Recruiting at 12 sites Tokyo University · Ōtsu, Shiga and 11 other locations · NCT07862088

• SGC001 is being tested to help predicted severe acute pancreatitis

  Researchers are testing SGC001 vs placebo in adults with predicted severe acute pancreatitis to see if it is safe and tolerable and to get a sense of any early effects.

  Recruiting Phase 2 Beijing Sungen Biomedical Technology Co., Ltd · Chengdu and 14 other locations · NCT07803965

• Fecal microbiota transplant to prevent infections after late-phase severe acute pancreatitis

  This trial will test whether giving healthy donor gut bacteria (fecal microbiota transplantation) through a feeding tube in the late phase of moderately severe or severe acute pancreatitis can prevent infectious complications.

  Recruiting Changhai Hospital · Fuzhou, Fujian and 11 other locations · NCT07464392

• How often splanchnic vein clots occur in acute pancreatitis and whether they relate to disease severity

  This project will see if people with acute pancreatitis develop blood clots in the splenic, portal, or superior mesenteric veins and whether those clots are linked to more severe illness.

  Recruiting Asian Institute of Gastroenterology, India · Hyderabad, Telangana · NCT07322978

• Fecal microbiota transplant for people with moderate to severe acute pancreatitis

  This trial will test whether a fecal microbiota transplant (FMT) can reduce late complications in adults with moderate to severe acute pancreatitis.

  Recruiting at 2 sites Changhai Hospital · Shanghai, Shanghai Municipality and 1 other locations · NCT07153809

• Blood markers to detect infected pancreatic necrosis

  We will test whether specific blood markers can help predict or diagnose infected pancreatic necrosis in adults with necrotizing pancreatitis.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT06899087

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.